

ATTACHMENT A
SEGMENT INFORMATION
STARPHARMA POOLED DEVELOPMENT LIMITED

PRIMARY BASIS - BUSINESS SEGMENTS
YEAR ENDING 30 JUNE, 2002

	VIROLOGY \$000's	ANGIOGENESIS	OTHER PHARMACEUTICAL \$000's	DENDRITIC NANOTECHNOLOGIES LIMITED \$000's	UNALLOCATED \$000's	CONSOLIDATED TOTAL \$000's
REVENUE						
External Revenue	0	384	0	1	944	1,329
Intersegment Revenue	0	0	0	0	0	0
Total revenue	0	384	0	1	944	1,329
Share of Net Profit of Associates	0	0	0	0	0	0
Total segment Revenue	0	384	0	1	944	1,329
SEGMENT RESULT						
Profit/(Loss) from Ordinary Activities before Income Tax	(4,104)	(1,415)	(1,232)	(1,907)	752	(7,906)
DEPRECIATION & AMORTISATION						
Depreciation	80	80	20	27	20	227
Amortisation - Goodwill	0	0	0	0	0	0
Non-Cash Expenses	0	0	0	0	0	0
Total Depreciation & Amortisation	80	80	20	27	20	227
LIABILITIES						
Total Segment Liabilities	0	0	0	66	1,285	1,351
ASSETS						
Total Segment Assets	531	886	734	637	15,398	18,186
SEGMENT ASSETS ACQUIRED DURING THE REPORTING PERIOD						
Property, Plant & Equipment	237	237	59	377	59	970

SEGMENT INFORMATION
STARPHARMA POOLED DEVELOPMENT LIMITED

ATTACHMENT A - CONTINUED
SECONDARY BASIS - GEOGRAPHIC SEGMENTS
YEAR ENDING 30 JUNE, 2002

	AUSTRALIA	USA	CONSOLIDATED TOTAL
REVENUE			
External Revenue	1,328	1	1,329
SEGMENT RESULT			
Profit/(Loss) from Ordinary Activities before Income Tax	(6,774)	(1,132)	(7,906)
ASSETS			
Total Segment Assets	17,549	637	18,186
SEGMENT ASSETS ACQUIRED DURING THE REPORTING PERIOD			
Property, Plant & Equipment	593	377	970